Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4496064 | 0.91 | APP (0.35) | APPHCRTR2SIGMAR1 | |
| SCHEMBL842297 | 0.81 | HCRTR2 (0.35) | HCRTR2 | |
| SCHEMBL841485 | 0.81 | ACHE (0.33) | NR1D1CTSL | |
| SCHEMBL862345 | 0.73 | — | — | |
| SCHEMBL862173 | 0.72 | PPARG (0.35) | HCRTR2 | |
| SCHEMBL862172 | 0.71 | APP (0.34) | APPHCRTR2 | |
| SCHEMBL878957 | 0.67 | APP (0.33) | APP | |
| SCHEMBL12060501 | 0.67 | APP (0.33) | APP | |
| SCHEMBL12060741 | 0.67 | PPARG (0.32) | — | |
| SCHEMBL878934 | 0.67 | PPARG (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143057-B2 | Chelating agents and highly luminescent and stable chelates and their use | WALLAC OY (FI) | 2012-03-27 | — | — | US | disclosed |
| US-8071626-B2 | Chromophoric moiety comprises trialkoxyphenylpyridyl groups; biochemical conjugation; for solid phase synthesis of oligonucleotides and oligopeptides; magnetic resonance imaging; positron emission tomography | WALLAC OY (FI) | 2011-12-06 | — | — | US | disclosed |
| US-20100036102-A1 | NOVEL CHELATING AGENTS AND HIGHLY LUMINESCENT AND STABLE CHELATES AND THEIR USE | WALLAC OY (FI) | 2010-02-11 | — | — | US | disclosed |
| US-20080167443-A1 | Novel chelating agents and highly luminescent and stable chelates and their use | WALLAC OY (FI) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036102-A1 | NOVEL CHELATING AGENTS AND HIGHLY LUMINESCENT AND STABLE CHELATES AND THEIR USE | CLTA, CLTC, FOLH1 | APP 3874/4885L3MBTL1 676/4885NR1D1 4441/4885 |
| US-20080167443-A1 | Novel chelating agents and highly luminescent and stable chelates and their use | CLTA, CLTC, FOLH1 | APP 3874/4885L3MBTL1 676/4885NR1D1 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.